Blood
Articles in this Issue
RXR agonist IRX4204 enhances BCMA CAR-T-cell efficacy by suppressing ferroptosis via CHAC1 downregulation
Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy targeting B cell maturation antigen (BCMA) shows remarkable efficacy in m...
Filamin-a expression in Acute Myeloid Leukemia: A multi-omic analysis of prognostic, metabolic and therapeutic implications.
Abstract Introduction: Filamin A (FLNA) is a multifunctional actin-binding protein involved in cytoskeletal remodeling, cell migration, cell...
Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes
Abstract Introduction: Idecabtagene vicleucel (Ide-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therap...
Real-world survival outcomes with first-line venetoclax therapy in AML
Abstract Introduction: Venetoclax, a selective BCL-2 inhibitor combined with a hypomethylating agent (azacitidine or decitabine), has become...
A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias
Abstract Background and Significance: Menin complexes with KMT2A and drives leukemic transformation in acute leukemias with aberrant homeobo...
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients
Abstract Background: Clinical outcomes in transplant eligible (TE) newly diagnosed myeloma (NDMM) patients continue to improve, which highli...
Visualizing geographic variation and systemic inequities of disease burden and CAR T-cell therapy access in multiple myeloma in the US
Abstract INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapies have emerged as a transformative treatment for relapsed/refractory m...
AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.
Abstract Introduction: Patients with lower-risk myelodysplastic syndrome (LR-MDS) benefit from treatment of clinically significant anemia wi...
Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML
Abstract Abstract Purpose The standard “3+7” daunorubicin-cytarabine (DA) induction regimen for acute myeloid leukemia (AML) demonstrates lim...
Real-world analysis of time spent at home for patients with secondary acute myeloid leukemia treated with CPX-351 or venetoclax plus azacitidine in England
Abstract Adults with secondary acute myeloid leukemia (sAML) face a significant treatment burden with prolonged time in hospital impacting t...
Protein expression signatures reveal age-specific risk patterns in B-ALL
Abstract Introduction Current B-cell acute lymphoblastic leukemia (B-ALL) risk stratification relies on clinical and genetic features, but o...
Characterisation of the wnt signalling responsive surfaceome of myeloid cells reveals PLP2 as a regulator of haematopoietic cell proliferation and monocytic differentiation
Abstract Acute myeloid leukaemia (AML) remains the most prevalent myeloid malignancy with persistently poor outcomes despite recent therapeu...
Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study
Abstract Background: Patients with relapsed or refractory (R/R) aggressive B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLB...
CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl
Abstract Introduction Relapsed or refractory T-lymphoblastic leukemia/lymphoma (RR T-ALL/LBL) has a poor prognosis and limited therapeutic o...
A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress
Abstract Background and Significance: Approximately 10% of cases of acute myeloid leukemia (AML) feature an isocitrate-dehydrogenase 1 gene...
Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians
Abstract Background: Bispecific Antibody (BsAb) therapy has improved outcomes in patients (pts) with relapsed/refractory large B-cell lymphom...
Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients
Abstract Introduction The International Prognostic Index (IPI) is a widely used tool for risk stratification of newly diagnosed large B-cell...
The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma and has shown a significant global rise in...
Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy is an effective therapy for patients (pts) who suffer from relapsed /...
Polatuzumab vedotin retains potent activity against CD79B mutations: Preclinical and clinical efficacy in diffuse large B-cell lymphoma
Abstract Background Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug conjugate delivering monomethyl auristatin E...
A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase
Abstract Introduction: Adenosine triphosphate (ATP)-competitivetyrosine kinase inhibitors (TKIs) are part of the current treatment landscape...
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
Abstract BTK degraders promote proteasomal degradation of BTK and can overcome resistance to covalent and noncovalent BTK inhibitors in pati...
Development and evaluation of a protein language model-based prediction model for acute graft-versus-host disease in HLA-mismatched hematopoietic stem cell transplantation
Abstract Introduction The biological heterogeneity of human leukocyte antigen (HLA) molecules, including differences in...
Catheter-related risk factors for neonatal venous thrombo-embolism: A systematic review of the literature
Abstract BACKGROUND Neonates are at high-risk of venous thrombo-embolism (VTE); central venous catheter (CVC) are related to 90% of VTE in th...
Effectiveness and safety of splenectomy or thrombopoietin receptor agonists as second-line treatments for patients with immune thrombocytopenia in a real-world setting
Abstract According to current guidelines, corticosteroids are well established as the first-line treatment for immune thrombocytopenia (ITP)...